146780-08-7

Basic information

• Product Name: diethyl 3-trifluoromethylbenzylphosphonate
• Synonyms: diethyl 3-trifluoromethylbenzylphosphonate;{[3-(Trifluoromethyl)phenyl]methyl}phosphonic acid diethyl ester
• CAS NO: 146780-08-7
• Molecular Formula: C₁₂H₁₆F₃O₃P
• Molecular Weight: 296.22
• Mol File: 146780-08-7.mol

Chemical Properties

• Boiling Point: 282-296°C/760 mmHg
• Flash Point: >110℃
• Appearance: /
• Density: 1.223 g/mL at 25 °C
• Refractive Index: n20/D1.455
• CAS DataBase Reference: diethyl 3-trifluoromethylbenzylphosphonate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl 3-trifluoromethylbenzylphosphonate(146780-08-7)
• EPA Substance Registry System: diethyl 3-trifluoromethylbenzylphosphonate(146780-08-7)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 146780-08-7(Hazardous Substances Data)

Upstream product

• 402-23-3 1-bromomethyl-3-trifluoromethylbenzene 
• 705-29-3 3-Trifluoromethylbenzyl chloride 
• 122-52-1 triethyl phosphite 
• 349-75-7 3-(trifluoromethyl)benzyl alcohol 

Downstream Products

• 847186-64-5 E,E-1,4-di(m-trifluoromethyl)phenyl-1,3-butadiene 
• 1370449-31-2 (E)-4-(2-methylstyryl)pyridine 
• 536739-11-4 [(R)-Hydroxy-(3-trifluoromethyl-phenyl)-methyl]-phosphonic acid diallyl ester 
• 536739-10-3 [(S)-Hydroxy-(3-trifluoromethyl-phenyl)-methyl]-phosphonic acid diallyl ester 
• 536739-01-2 (3-trifluoromethyl-benzyl)-phosphonic acid diallyl ester 
• 536739-18-1 [(S)-Hydroxy-(3-trifluoromethyl-phenyl)-methyl]-phosphonic acid 
• 176713-97-6 [2-Phenyl-1-(3-trifluoromethyl-phenyl)-ethyl]-phosphonic acid diethyl ester 

Relevant articles and documents

A new insight into the push-pull effect of substituents via the stilbene-like model compounds

In this paper, authors report on 1-pyridyl-2-arylethenes, 1-furyl-2-arylethylenes, 1,2-diphenylpropylenes and substituted cinnamyl anilines as stilbene-like model compounds to investigate the factors dominating the push-pull effect of substituents via usi

Vinyl-Stilbene Compounds and Uses Thereof

The present invention relates to a biphenyl - stilbene (Vinyl-stilbene) - based compound and a pharmaceutical composition for preventing or treating norovirus infection comprising the same as an active ingredient. The present invention can be usefully used as a pharmaceutical composition for treating norovirus infection by showing superior norovirus inhibitory activity and lower cell toxicity as compared to previously known compounds.

The development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a typical survival time between three to five years. Two drugs, pirfenidone and nintedanib have been approved for the treatment of IPF, but they have limited efficacy. Thus, th

Determination and application of the excited-state substituent constants of pyridyl and substituted phenyl groups

Thirty six 1-pyridyl-2-arylethenes XCH=CHArY (abbreviated XAEY) were synthesized, in which, X is 2-pyridyl, 3-pyridyl and 4-pyridyl and Y is OMe, Me, H, Br, Cl, F, CF3, and CN. Their ultraviolet absorption spectra were measured in anhydrous ethanol, and their wavelengths of absorption maximum λmax were recorded. Also, the 234 λmax values of 1-substituted phenyl-2-arylethylene compounds (XAEY, where X is substituted phenyl) were collected. The excited-state substituent constants (Formula presented.) of three pyridyl groups and 23 substituted phenyl groups (total of 26) were obtained by means of curve-fitting method. Taking the λmax values of 358 samples of bi-arylethene derivatives as a data set and 126 samples of bi-aryl Schiff bases (including nine compounds synthesized by this work) as another data set, quantitative correlation analyses were performed by employing the obtained (Formula presented.) as a parameter, and good results were obtained for the two data sets. The reliability of the obtained (Formula presented.) values was verified. The results of this paper can provide excited-state substituent constants for the study and application of optical properties of conjugated organic compounds containing aryl groups.

Identification of novel non-nucleoside vinyl-stilbene analogs as potent norovirus replication inhibitors with a potential host-targeting mechanism

Norovirus (NV), is the most common cause of acute gastroenteritis worldwide. To date, there is no specific anti-NV drug or vaccine to treat NV infections. In this study, we evaluated the inhibitory effect of different stilbene-based analogs on RNA genome replication of human NV (HNV) using a virus replicon-bearing cell line (HG23). Initial screening of our in-house chemical library against NV led to the identification of a hit containing stilbene scaffold 5 which on initial optimization gave us a vinyl stilbene compound 16c (EC50 = 4.4 μM). Herein we report our structure-activity relationship study of the novel series of vinyl stilbene analogs that inhibits viral RNA genome replication in a human NV-specific manner. Among these newly synthesized compounds, several amide derivatives of vinyl stilbenes exhibited potent anti-NV activity with EC50 values ranging from 1 to 2 μM. A trans-vinyl stilbenoid with an appended substituted piperazine amide (18k), exhibited potent anti-NV activity and also displayed favorable metabolic stability. Compound 18k demonstrated an excellent safety profile, the highest suppressive effect, and was selective for HNV replication via a viral RNA polymerase-independent manner. Its potential host-targeting antiviral mechanism was further supported by specific activation of heat shock factor 1-dependent stress-inducible pathway by 18k. These results suggest that 18k might be a promising lead compound for developing novel NV inhibitors with the novel antiviral mechanism.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

Synthesis and electronic spectra of substituted oligo(phenylenevinylene)s

A series of substituted oligo(p-phenylenevinylene)s (OPVs) with five benzene rings was prepared via PO-activated olefinations and Knoevenagel condensations. The central ring is substituted with two octyloxy groups to ensure good solubility of the OPVs and the lateral styrene units carry further substituents, with either electron-accepting or donating character and also combinations thereof. The spectral features of these OPVs are dominated by the basic chromophore; further auxochrome groups on the lateral rings (meta and para positions) shift the absorption and emission spectra only slightly to longer wavelengths. Significant bathochromic shifts (absorption ca 20 nm, emission ca 40 nm) are observed for OPVs with cyano groups on the terminal vinylene segments. The absorption spectra are independent from the concentration and solvatochromism is very small. The OPVs are photochemically stable to near-UV irradiation (366 nm) in neutral solution, whereas mid-UV irradiation (254 nm) causes decomposition of the chromophore. The presence of traces of acids or amines leads to different photochemical pathways. Copyright

Substituted phosphonic acids and derivatives useful in treating bone wasting diseases

Compounds represented by the formula I: STR1 are disclosed as agents for use in treating bone wasting diseases.

Trifluoromethybenzylphosphonates useful in treating osteoporosis

Novel benzylphosphonate compounds of the general formula I: STR1 are disclosed as useful in treating bone wasting diseases including postmenopausal osteoporosis in increasing in mammals bone formation and bone mass.

Benzylphosphonic acid inhibitors of human prostatic acid phosphatase

A series of α-substituted benzylphosphonic acids is described as inhibitors of human prostatic acid phosphatase, an enzyme has been used as a model to study aryl phosphatases. The most potent inhibitors in this series are 2-trifluoromethylbenzhydrylphosphonic acid (9 μM), and α-(2-phenylethyl)benzylphosphonic acid (14 μM). The structure-activity studies suggest that bulk tolerance beyond the phosphate binding area limits the steric or hydrophobic contribution to inhibitor potency achieved through α-carbon substitution.